Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment
- 30 November 2011
- journal article
- review article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 12 (6), 360-368
- https://doi.org/10.1016/j.cllc.2011.02.003
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaNew England Journal of Medicine, 2009
- Expression of ERCC1 and class III β-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxelLung Cancer, 2008
- Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapyLung Cancer, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences of the United States of America, 2007
- The spindle-assembly checkpoint in space and timeNature Reviews Molecular Cell Biology, 2007
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004